Last reviewed · How we verify
Advaxis, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
0 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
Therapeutic area mix
- Oncology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Agenus Inc. · 1 shared drug class
- European Organisation for Research and Treatment of Cancer - EORTC · 1 shared drug class
- Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 1 shared drug class
- Merck KGaA, Darmstadt, Germany · 1 shared drug class
- National Cancer Institute (NCI) · 1 shared drug class
- TD Vaccines A/S · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Advaxis, Inc.:
- Advaxis, Inc. pipeline updates — RSS
- Advaxis, Inc. pipeline updates — Atom
- Advaxis, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Advaxis, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advaxis-inc. Accessed 2026-05-14.